A Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of ATA3219, Allogeneic Anti-CD19 Chimeric Antigen Receptor T-cell Therapy, in Subjects with Relapsed/Refractory B-cell non-Hodgkin Lymphoma
-
Enrollment
This study is currently enrolling. -
Research Area
Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Atara Biotherapeutics, Inc.
To characterize the safety and tolerability of ATA3219 monotherapy in subjects with R/R B-cell NHL. To determine the recommended phase 2 dose (RP2D) of ATA3219 as monotherapy in subjects with R/R B-cell NHL. To characterize the PK profile of ATA3219. To evaluate the preliminary efficacy of ATA3219 as monotherapy in subjects with R/R B-cell NHL. To assess immunogenicity and other biomarkers.
Enrollment Form
This study is currently enrolling.